Form 4: Perceptive Advisors Reports LionaBio Stock Option Grant

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund Ltd., reported a stock option grant for 28,000 shares of LionaBio, Inc. common stock.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund Ltd. have filed a Form 4 with the SEC detailing changes in beneficial ownership.
• The filing reports the acquisition of a stock option to purchase 28,000 shares of LionaBio, Inc. (LONA) common stock.
• The option has an exercise price of $8.35 and was granted on June 23, 2026, with an expiration date of June 22, 2036.
• Vesting of the shares subject to the option will occur on the earlier of June 23, 2027, or the day before the next annual stockholder meeting after June 22, 2026.
• The option was granted under LionaBio's Outside Director Compensation Policy.
• Joseph Edelman is identified as the managing member of Perceptive Advisors LLC, which serves as the investment manager for Perceptive Life Sciences Master Fund Ltd.
• Perceptive Advisors LLC may be deemed to have an indirect pecuniary interest in the securities due to potential management fee offsets related to director compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to directors rather than a sale or purchase of shares that would indicate a stronger sentiment.

Positives

• Grant of stock options indicates potential for future value appreciation for the reporting persons.
• The option grant is part of the company's compensation policy for outside directors, suggesting alignment between management and board incentives.
• The reporting persons are significant stakeholders, with Perceptive Advisors LLC and Perceptive Life Sciences Master Fund Ltd. identified as 10% owners and directors.

Negatives

• The filing only reports an option grant, not the exercise or sale of shares, so no immediate financial gain is realized.
• The vesting schedule is tied to future dates, meaning the benefit is not immediate.

Risks

• The value of the stock option is contingent on the future performance of LionaBio, Inc. and its stock price.
• There is a risk that the stock price may not appreciate sufficiently to make the option exercise profitable.
• The disclaimer regarding beneficial ownership for Section 16 purposes suggests potential complexities in ownership structure and reporting.

Future Outlook

The future outlook for the stock option is dependent on the performance of LionaBio, Inc. and its stock price, with vesting scheduled for June 23, 2027, or prior to the next annual meeting after June 22, 2026, and an expiration date of June 22, 2036.

Management Comments

• Joseph Edelman, as managing member of Perceptive Advisors LLC and through its role as investment manager for Perceptive Life Sciences Master Fund Ltd., is involved in the reporting of these securities.
• The reporting entities disclaim beneficial ownership except to the extent of indirect pecuniary interest, indicating a nuanced ownership structure.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, including option grants, which are common in the biotechnology sector as a form of executive and director compensation.

Related Party Transactions

• The stock option grant to Joseph Edelman, a director, is a related party transaction, as he is also affiliated with Perceptive Advisors LLC and Perceptive Life Sciences Master Fund Ltd., which are 10% owners.

Stakeholder Impact

• Shareholders: The option grant does not immediately dilute share count but represents potential future dilution if exercised. It also signals continued board engagement.
• Employees: No direct impact mentioned.
• Management: Indirectly impacted through the compensation policy and potential fee offsets for Perceptive Advisors LLC.
• Creditors: No direct impact mentioned.

Next Steps

• The reporting persons will hold the stock option, with vesting occurring according to the specified schedule.
• The option can be exercised between the vesting date and the expiration date of June 22, 2036.

Key Dates

Keywords

Form 4, SEC Filing, Stock Option, Beneficial Ownership, Perceptive Advisors LLC, LionaBio Inc., LONA, Joseph Edelman, Director Compensation, Insider Trading